Initial Dosage Optimization of Tacrolimus in Connective Tissue Disease-Associated Interstitial Lung Disease Patients: An Exploratory Study.
Tacrolimus has emerged as a promising therapeutic agent for connective tissue disease-associated interstitial lung disease (CTD-ILD) patients. However, its clinical application is substantially hindered by high interindividual pharmacokinetic variability and a narrow therapeutic window, which poses critical challenges particularly for the formulation of the initial dosage regimen.
A retrospective real-world study was conducted on 22 CTD-ILD patients receiving tacrolimus therapy. Comprehensive clinical data were systematically collected, encompassing demographic characteristics, routine physiological and biochemical parameters, and detailed concomitant medication records. A population pharmacokinetic (PPK) model for tacrolimus in CTD-ILD patients was developed using the nonlinear mixed-effects modeling approach implemented in NONMEM software. Monte Carlo simulation was subsequently performed to recommend the optimal initial dosage regimen of tacrolimus for CTD-ILD patients.
Based on the results of the model, we proposed initial dosing regimens: for CTD-ILD patients, the recommended initial tacrolimus dosage was 0.10 mg/kg across the body weight range of 50-100 kg, which yielded a target attainment probability of 89.1-93.5%, a probability below 5 ng/mL was 6.3-10.9%, a probability above 10 ng/mL was 0-0.2%.
This was an exploratory single-center PPK analysis recommending the initial dosage of tacrolimus for CTD-ILD patients. We proposed the 0.10 mg/kg regimen as a preliminary model-derived starting dose, which warranted prospective validation and therapeutic drug monitoring (TDM). Given the inherent limitations including the relatively small sample size, lack of external validation, further large-scale prospective studies were warranted to confirm these conclusions.
A retrospective real-world study was conducted on 22 CTD-ILD patients receiving tacrolimus therapy. Comprehensive clinical data were systematically collected, encompassing demographic characteristics, routine physiological and biochemical parameters, and detailed concomitant medication records. A population pharmacokinetic (PPK) model for tacrolimus in CTD-ILD patients was developed using the nonlinear mixed-effects modeling approach implemented in NONMEM software. Monte Carlo simulation was subsequently performed to recommend the optimal initial dosage regimen of tacrolimus for CTD-ILD patients.
Based on the results of the model, we proposed initial dosing regimens: for CTD-ILD patients, the recommended initial tacrolimus dosage was 0.10 mg/kg across the body weight range of 50-100 kg, which yielded a target attainment probability of 89.1-93.5%, a probability below 5 ng/mL was 6.3-10.9%, a probability above 10 ng/mL was 0-0.2%.
This was an exploratory single-center PPK analysis recommending the initial dosage of tacrolimus for CTD-ILD patients. We proposed the 0.10 mg/kg regimen as a preliminary model-derived starting dose, which warranted prospective validation and therapeutic drug monitoring (TDM). Given the inherent limitations including the relatively small sample size, lack of external validation, further large-scale prospective studies were warranted to confirm these conclusions.
Authors
Zhang Zhang, Jin Jin, Wang Wang, Ding Ding, Zhao Zhao, Ping Ping, Du Du, He He, Zhang Zhang, Wang Wang
View on Pubmed